SOX-based CRT for Esophageal Cancer.
Key facts
- Who runs it
- Zhejiang Provincial People's Hospital
- Where
- China1 site in 1 countryChoose a country to see its locations
- Trial code
- Status
- Withdrawn
- Phase
- Phase 1/2
- Started
- 1 May 2019
- Ended
- 31 Dec 2023
- Type of study
- Interventional
- Treatments tested
- Oxaliplatin
- S-1 capsule
- Intensity modulated radiotherapy (IMRT)
- Record updated
- 21 September 2023
- Why it stopped
- No eligible patients enrolled. We have to withdraw the trial.
Who can take part
- Age
- 18 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (17)Hide the full registry criteria
Who can take part
- Cytopathological confirmed esophageal cancer with unresectable locally advanced diseases
- Age of 18-70
- ECOG performance status: 0-1
- No treatments prior to enrollment
- Patients must have measurable or evaluable disease with at least one tumor mass maximum diameter ≥10mm by multi-slice spiral CT or MR scan. Imaging exam must be performed within 15 days from enrollment
- Normal marrow function and the blood tests must be collected within 7 days from enrollment with a hemoglobin of ≥90g/L, an white blood cell (WBC) counts of ≥4.0×109/L,a neutrophil count of ≥2.0×109/L, , a platelet count of ≥100×109/L, a total bilirubin (TBil) of ≤1.0 upper normal limitation (UNL), a creatinine (Cr) of ≤ 1.0 UNL, alanine aminotransferase (ALAT) and aspartate aminotransferase (ASAT) of ≤2.5 UNL, Alkaline phosphatase (AKP) ≤5.0 UNL. Pulmonary function (FEV1 >1L), and no major electrocardiogram abnormalities
- Normal electrocardiogram results and no history of congestive heart failure
- Patients must be with good compliance and agree to accept follow-up of disease progression and adverse events
- Informed consent signed
Who cannot take part
- Prior treatments of chemotherapy or irradiation
- Poor bone marrow, liver and kidney functions, which would make chemotherapy intolerable
- Contraindication for irradiation: complete obstruction of esophagus, deep esophageal ulcer, fistula to mediastinum, or haematemesis
- Clinically significant and uncontrolled major medical conditions including but not limited to: active uncontrolled infection, symptomatic congestive heart failure, Unstable angina pectoris or cardiac arrhythmia, psychiatric illness/ social situation that would limit compliance with study requirements; any medical condition, which in the opinion of the study investigator places the subject at an unacceptably high risk for toxicities
- The subject has had another active malignancy within the past five years except for cervical cancer in site, in situ carcinoma of the bladder or non-melanoma carcinoma of the skin
- Participating in other clinical trials
- Pregnancy, breast feeding, or not adopting birth control
- Weight loss of 20% or more of normal body weight within 3 months
Where is this trial?
It has locations in one country. Choose a country to see its locations.
What happens in this trial
What the trial wants to find out
Patients with esophageal cancer that had locally advanced diseases or with unresectable diseases are being asked to participate in this phase I/II study.
Read full original descriptionShow less
This phase I/II study is being conducted to determine the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), and efficacy of IMRT combined with S-1 and Oxaliplatin (SOX) based chemotherapy for unresectable locally advanced esophageal cancer.
The group in the trial
- SOX-based ChemoradiotherapyTreatment being tested
IMRT is delivered with a daily fraction of 1.8 Gy to a total dose of 50.4 Gy over 5 weeks. Concurrent Oxaliplatin (3 levels for phase I: 110mg/m², 120 mg/m² and 130 mg/m², d1) and fixed dose of S-1 (80mg/ m², d1-14) are administered concurrently with IMRT, every 4 weeks. The recommended dose of Oxaliplatin are then further evaluated in the Phase II setting.
Treatment: Oxaliplatin, S-1 capsule, and Intensity modulated radiotherapy (IMRT)
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase I/II Study of S-1 and Oxaliplatin Based Definitive Concurrent Chemoradiotherapy (SOX-CRT-01) for Unresectable Locally Advanced Esophageal Cancer.
- Record updated
- 21 September 2023